Fermentas

US patents awarded to University of California, Hospital for Sick Children, Thermo Fisher, Fujifilm, Abbott, and Novartis.

The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR.

The acquisition will add reagents for nucleic acid and protein purification, restriction and modifying enzymes, and other life science research and diagnostic tools to Thermo's Analytical Technologies portfolio.

When considering Thermo's planned acquisition of molecular biology tool shop Fermentas, its acquisition earlier this year of Finnish PCR firm Finnzymes, and recent product launches, it appears as if the company plans to make a run at disease diagnostics, food testing, and other PCR-based testing markets.

Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."

Based in Ontario with principal operations in Lithuania, Fermentas offers reagents for nucleic acid and protein purification, restriction and modifying enzymes, and various PCR products.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.